Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your experience. Save up to 40% More details

Valeant Pharmaceuticals: Why We’re Seeing Declines

By CNA Finance (Joshua Rodriguez)Stock MarketsFeb 29, 2016 11:44AM ET
Valeant Pharmaceuticals: Why We’re Seeing Declines
By CNA Finance (Joshua Rodriguez)   |  Feb 29, 2016 11:44AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items

Valeant Pharmaceuticals (N:VRX) is having a rough day in the market today after a series of mixed news. On the good side of the coin, CEO J. Michael Pearson has completed a full recovery and has returned to his post at VRX. On the bad side of things, results have been delayed, leading to a bit of uncertainty. Today, we'll talk about the return of Pearson, what results were delayed, and what we can expect to see from VRX moving forward. So, let's get right to it...

J. Michael Pearson Has Returned

At possibly the worst timing, J. Michael Pearson took a medical leave from VRX more than a month ago has he suffered from a severe case of pneumonia. At this time, the stock struggled quite a bit as investors worried about the company's recovery without Pearson involved. Nonetheless, the team appointed to take on his role did incredibly well. Today, it was announced that Pearson would be returning to his post at Valeant effective immediately. This is incredibly good news. While the team appointed has done well, the company is definitely in need of Pearson's leadership.

While this is good news, there is some bad news that came along with the announcement. VRX was scheduled to report preliminary result from Q4 and provide updated guidance to investors relatively soon. However, given the timing of Pearson's return, the investors' call has to be pushed back. There is already a bit of uncertainty with regard to what investors can expect given the recent hardships Valeant Pharmaceuticals has faced. As a result, the delay adds to the uncertainty and is becoming a big reason for declines. In a statement, J. Michael Pearson had the following to say with regard to his return...

I want to express my sincere gratitude to Howard for his willingness to step in and lead the company through a challenging period... I realize that recent events are disappointing to everyone and it is my responsibility to set the appropriate tone for the organization. My immediate priority will be to build stronger relationships with important constituents, such as managed care and other channel partners, regulators and government representatives, while improving Valeant's reporting procedures, internal controls and transparency. I will focus on the retention and enhancement of our management teams and employee groups around the world and ensure that we maintain a culture that adheres to the highest ethical standards. Finally, we expect to deliver strong operating performance going forward by working closely with physicians to better serve patients, and we remain committed to reducing our leverage.”

How The Market Reacted To The News

As investors, we know that the news moves the market. In this particular case, there was a bit of good news in the fact that Pearson has made it back to VRX. However, there was also a bit of bad news in the fact that results and guidance are being delayed. Given the current circumstances revolving around Valeant, the delay in results and guidance is leading to investor fear. As a result, we're seeing sharp declines in the value of the stock today. Currently (10:10), VRX is trading at $73.20 per share after a loss of $7.45 per share or 9.24% thus far today.

What We Can Expect To See Moving Forward

While I know I'm probably going to catch some flack for the bears for my opinion here, I believe that we're going to see relatively positive movement out of VRX moving forward. The reality is that when we talk about Valeant, we're talking about an incredible company. While they have had to get over hurdles as of late, the company has a long list of great products and has put together a solid plan for growth. Now that Pearson is back, I'm expecting for things to move in the right direction relatively quickly. All in all, my view of VRX is positive.

Original post

Valeant Pharmaceuticals: Why We’re Seeing Declines

Related Articles

Michael Kramer
S&P 500 In Overbought Territory   By Michael Kramer - Aug 15, 2022 1

Stocks rallied last Friday, with the S&P 500 finishing higher by 1.7% to close around 4,280. At this point, the index has risen into overbought territory with an RSI now 71 and...

Valeant Pharmaceuticals: Why We’re Seeing Declines

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at’s discretion.

Write your thoughts here
Are you sure you want to delete this chart?
Post also to:
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Are you sure you want to delete this chart?
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
Sign up with Email